Precision BioSciences’s $1.6 billion worldwide immuno-oncology partnership agreement with Baxalta/Shire will win a Deals of Distinction™ award in the Life Sciences sector category at the 2016 Licensing Executives Society (LES) (U.S.A. & Canada) Annual Meeting.
The awards are presented annually to promote creative and innovative solutions and recognize the most exceptional IP business deals in three industry sectors, including High Technology, Life Sciences, and Chemicals, Energy, Environment and Materials.
The Deals of Distinction™ award will be presented at the 2016 Annual Meeting taking place October 23-26, 2016 in Vancouver, BC, Canada.
This Precision-Baxalta partnership is the seventh-largest value deal on the 2016 list of Top 15 Immuno-Oncology Collaborations published by Genetic Engineering & Biotechnology News. For additional information about this deal, please click here.
Smith Anderson acted as lead counsel to Precision BioSciences in the formation of the worldwide immuno-oncology partnership, which included a $105 million upfront payment to Precision. The collaboration with global biopharmaceutical company Baxalta (now a subsidiary of Shire) will utilize Precision’s genome editing expertise and technology with the potential to transform the treatment of multiple cancers through the development of allogeneic chimeric antigen receptor (CAR) T cell therapies. The Smith Anderson team was led by Life Sciences partners John Therien and Jason Brege.
About LES (U.S.A. and Canada)
Established in 1965, LES (USA & Canada) is a professional society of nearly 3,000 members engaged in the creation, commercial development, and orderly transfer of intellectual property. LES members include business executives, lawyers, accountants, consultants, and scientists and engineers; and those members represent innovation-oriented enterprises of all sizes, professional services firms, universities, and government labs. LES is a member society of the Licensing Executives Society International, Inc. (LESI), which has more than 10,000 members worldwide among 32 sister societies representing 90 countries. For more information about LES, visit www.lesusacanada.org.
About Precision BioSciences
Based in Durham, N.C., Precision BioSciences is a genome editing company dedicated to improving life. Our team seeks to solve significant problems in oncology, genetic disease, agriculture, and beyond via its ARCUS genome editing platform. ARCUS is Precision’s proprietary, nuclease-based genome editing platform which now encompasses an industry leading combination of site specificity, ease of delivery, and breadth of editing capabilities.